The global pharmaceutical contract development and manufacturing market is projected to reach USD 171.3 billion by 2026 from USD 120.6 billion in 2021, at a CAGR of 7.3% during the forecast period. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years. The small and medium-sized pharmaceutical companies segment accounted for the highest growth rate in the pharmaceutical contract development and manufacturing market, byend user, during the forecast period The pharmaceutical contract development and manufacturing market is segmented intobig pharmaceutical companies, small & medium-sized pharmaceutical companies, generic pharmaceutical companies, and other end users.The small and medium-sized pharmaceutical companies segment accounted for the highest growth rate in the pharmaceutical contract development and manufacturing market in 2021.
This segment’s high growth can be attributed to the increasing number of emerging pharmaceutical companies that lack the in-house capabilities to manufacture and develop complex formulations and drug products.
Biologics manufacturing services segment accounted for the highest CAGR Based on service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services.In 2021, the biologics manufacturing services segment accounted for the highest growth rate.
The major factor driving the growth of this segment is the growing demand for vaccines and biosimilars.
Asia Pacific: The fastest-growing countryin thepharmaceutical contract development and manufacturing market Thepharmaceutical contract development and manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.Asia Pacific is projected to register the highest CAGR during the forecast period.
This growth can be attributed to factors such as growth in the manufacturing sector, favorable government regulations, growing strategic expansions from leading companies, increasing emphasis on off-patent drugs, and the presence of a highly skilled workforce.
The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side- 80%and Demand Side 20% • By Designation: C-level - 25%, D-level - 20%, and Others - 55% • By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%
Lists of Companies Profiled in the Report: • Thermo Fisher Scientific Inc. (US) • Catalent, Inc. (US) • Lonza Group Ltd. (Switzerland) • Recipharm AB (Sweden) • Siegfried Holding AG (Switzerland) • WuXiAppTec (China) • Samsung Biologics (South Korea) • Boehringer Ingelheim International GmbH (Germany) • Piramal Pharma Solutions (India) • Vetter Pharma International GmbH (Germany) • FAMAR Health Care Services (France) • AbbVie Inc. (US) • Aenova Group (Germany) • Almac Group (UK) • Evonik Industries AG (Germany) • Cambrex Corporation (US) • CordenPharma International (Germany) • Albany Molecular Research Inc. (AMRI) (US) • FUJIFILM Corporation (Japan) • BioVectra (Canada)
Research Coverage: This report provides a detailed picture of thepharmaceutical contract development and manufacturing market.It aims at estimating the size and future growth potential of the market across different segments,such as the service, end user, and region.
The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical contract development and manufacturing marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
Our reports have been used by over 10K customers, including:
The global pharmaceutical CMO market was valued at USD 120.29 billion in 2020, and it is expected to reach USD 195.70 billion by 2026, registering a CAGR of 7.85% from 2021 to 2026. COVID-19 pandemic has had a beneficial effect on contract manufacturing services overall. There were multiple opportunities for CMOs in clinical trial manufacturing,...
The Indian CMO market is expected to register a CAGR of 13.3% during the period of 2021 - 2026. The rise in demand for injectable drugs, especially in cancer research, will upwardly trend the Indian pharmaceutical contract manufacturing market. Injectable drugs offer higher returns as compared to other drug formulation types. Therefore, higher...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Active Pharmaceutical Ingredients Market Report The active pharmaceutical ingredients market is expected to reach USD 266.80 billion by 2026, growing at a CAGR of 6.22%. The following factors are likely to contribute to the growth of...
The healthcare analytical testing services market is projected to reach USD 9.8 billion by 2026 from USD 5.6 billion in 2021, at a CAGR of 11.9%. Growth in the market is driven by the rising trend of outsourcing of analytical testing by pharmaceutical companies and medical device companies, an increasing number of clinical trials, and the...
The European Pharmaceutical Logistics Market is expected to grow at a CAGR of more than 4% during the forecast period. The market growth can be seen as a result of Covid-19, with an increase in pharmaceutical product imports (USD 361 billion) and exports (USD 524 billion) in the year 2020. Logistics is an essential segment of supply...
The pharmaceutical processing seals market is estimated to be USD 2.1 Billion in 2021 and is projected to reach USD 3.3 Billion by 2026, at a CAGR of 10.0%. Manufacturing equipment is the major application of pharmaceutical processing seals. Capacity expansion and constant innovation in the pharmaceutical industry are expected to drive the...
The pharmaceutical isolator market was valued at 5,966.07 million in 2021 and is projected to reach US$ 10,560.30 million by 2028; it is expected to grow at a CAGR of 8.5 % from 2021 to 2028. The growth of the pharmaceutical isolator market is attributed to factors such as an increase in investments by the pharmaceutical and biotechnology...
The aptamers market valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period. Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages...
256 pages •
By The Business Research Company
• Oct 2021
AI In Pharma Global Market Opportunities And Strategies To 2030: COVID-19 Growth and Change provides the strategists; marketers and senior management with the critical information they need to assess the global AI in pharma market as it emerges from the COVID 19 shut down. Description: Where is the largest and fastest...
The global western blotting market is projected to reach USD 1.4 billion by 2026 from USD 1.0 billion in 2021, at a CAGR of 6.7% during the forecast period. Technological advancements, increasing government funding in the field of biomedical research, growing demand for personalized medicine, and the rising prevalence of HIV are the key factors...
HIV AIDS Prevalence
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.